Neurocrine Biosciences (NBIX) Short-term Investments (2010 - 2026)

Neurocrine Biosciences has reported Short-term Investments for 17 years, with the latest figure at $1.0 billion in Q1 2026.

• For the quarter ending Q1 2026, Short-term Investments rose 40.07% year-over-year to $1.0 billion; the trailing twelve-month figure through Mar 2026 stood at $1.0 billion (up 40.07% YoY), and the FY2025 full-year result was $767.4 million, down 8.98% from the prior year.
• Short-term Investments for Q1 2026 stood at $1.0 billion, up from $767.4 million in the prior quarter.
• The five-year high for Short-term Investments was $1.0 billion in Q1 2026, with the low at $394.7 million in Q1 2022.
• Historically, Short-term Investments has averaged $757.1 million across 5 years, with a median of $780.5 million in 2023.
• Annual changes were most pronounced in 2022 — Short-term Investments fell 24.26% — and 2023, when it surged 100.35%.
• Neurocrine Biosciences' Short-term Investments stood at $726.4 million in 2022, then advanced by 7.45% to $780.5 million in 2023, then grew by 8.02% to $843.1 million in 2024, then dropped by 8.98% to $767.4 million in 2025, then jumped by 36.79% to $1.0 billion in 2026.
• The last three Short-term Investments figures came in at $1.0 billion (Q1 2026), $767.4 million (Q4 2025), and $774.6 million (Q3 2025), per Business Quant data.